180 related articles for article (PubMed ID: 15917157)
21. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study.
De Aloysio D; Rovati LC; Giacovelli G; Setnikar I; Bottiglioni F
Arzneimittelforschung; 2000 Mar; 50(3):293-300. PubMed ID: 10758784
[TBL] [Abstract][Full Text] [Related]
22. A comparison of transdermal and oral HRT for menopausal symptom control.
Akhila V; Pratapkumar
Int J Fertil Womens Med; 2006; 51(2):64-9. PubMed ID: 16881381
[TBL] [Abstract][Full Text] [Related]
23. [Aerodiol: the efficacy and tolerability of intranasal estrogen administration. An overview].
Genazzani AR; Cappagli B; Ciaponi M
Minerva Ginecol; 2003 Jun; 55(3):189-200. PubMed ID: 14581864
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
[TBL] [Abstract][Full Text] [Related]
25. Estrogen therapy: from women's choice to women's preference.
Lachowsky M
Climacteric; 2002 Jun; 5 Suppl 2():46-9. PubMed ID: 12482111
[TBL] [Abstract][Full Text] [Related]
26. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
[TBL] [Abstract][Full Text] [Related]
27. Efficacy, safety and acceptability of a seven-day, transdermal estradiol patch for estrogen replacement therapy.
Jarupanich T; Lamlertkittikul S; Chandeying V
J Med Assoc Thai; 2003 Sep; 86(9):836-45. PubMed ID: 14649968
[TBL] [Abstract][Full Text] [Related]
28. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study.
Sonnet E; Lacut K; Roudaut N; Mottier D; Kerlan V; Oger E
Clin Endocrinol (Oxf); 2007 May; 66(5):626-31. PubMed ID: 17492948
[TBL] [Abstract][Full Text] [Related]
29. Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms.
Al-Azzawi F; Buckler HM;
Climacteric; 2003 Jun; 6(2):118-27. PubMed ID: 12841882
[TBL] [Abstract][Full Text] [Related]
30. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.
Cieraad D; Conradt C; Jesinger D; Bakowski M
Arch Gynecol Obstet; 2006 May; 274(2):74-80. PubMed ID: 16491367
[TBL] [Abstract][Full Text] [Related]
31. Continuous combined hormone replacement therapy relieves climacteric symptoms and improves health-related quality of life in early postmenopausal women.
Pitkin J; Smetnik VP; Vadász P; Mustonen M; Salminen K; Ylikangas S;
Menopause Int; 2007 Sep; 13(3):116-23. PubMed ID: 17785037
[TBL] [Abstract][Full Text] [Related]
32. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women.
Rachoń D; Suchecka-Rachoń K; Hak Ł; Myśliwska J
Menopause; 2006; 13(5):840-5. PubMed ID: 16894332
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch 40 and Estrapatch 60) with a twice week system.
Raynaud JP; Lévrier M; Calaf J; Laur C; Pélissier C
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):309-18. PubMed ID: 15860275
[TBL] [Abstract][Full Text] [Related]
34. Vasomotor symptoms and quality of life in previously sedentary postmenopausal women randomised to physical activity or estrogen therapy.
Lindh-Astrand L; Nedstrand E; Wyon Y; Hammar M
Maturitas; 2004 Jun; 48(2):97-105. PubMed ID: 15172083
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms.
Speroff L; Haney AF; Gilbert RD; Ellman H;
Menopause; 2006; 13(3):442-50. PubMed ID: 16735941
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.
Davis SR; van der Mooren MJ; van Lunsen RH; Lopes P; Ribot C; Rees M; Moufarege A; Rodenberg C; Buch A; Purdie DW
Menopause; 2006; 13(3):387-96. PubMed ID: 16735935
[TBL] [Abstract][Full Text] [Related]
37. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
[TBL] [Abstract][Full Text] [Related]
38. Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study.
Davis SR; Stuckey BG; Norman RJ; Papalia MA; Drillich A; Bell RJ
Menopause; 2008; 15(6):1065-9. PubMed ID: 18806686
[TBL] [Abstract][Full Text] [Related]
39. Low-dose transdermal estradiol for symptomatic perimenopause.
Shulman LP; Harari D
Menopause; 2004; 11(1):34-9. PubMed ID: 14716180
[TBL] [Abstract][Full Text] [Related]
40. Identifying meaningful differences in vasomotor symptoms among menopausal women.
Wyrwich KW; Spratt DI; Gass M; Yu H; Bobula JD
Menopause; 2008; 15(4 Pt 1):698-705. PubMed ID: 18369313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
